Key Metrics
7.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
103
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.86
5-Year SI
5-year SI
- N/A 2-year SI
- 0.88 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Immunology
SJR
- Q2 Immunology
- Q1 Pharmacology
- Q2 Cancer Research
- Q1 Immunology and Allergy
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.8
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
5 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
17%
4 to 6 months
40%
7 to 9 months
31%
Above 9 months
13%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Immune checkpoint inhibitors
- Odds ratio
- Confidence interval
- Pembrolizumab
- Nivolumab
- Autologous tumor
- Melanoma
- Tumor-infiltrating lymphocytes
- Overall survival
- Advanced melanoma
- Colorectal cancer
- Hazard ratio
- Ipilimumab
- Avelumab
- Soft tissue sarcoma
- Clinical trial
- Attributable risk
- Immunotherapy
Journal Specifications
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1991 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Journal of Immunotherapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Machine Learning-enhanced Signature of Metastasis-related T Cell Marker Genes for Predicting Overall Survival in Malignant Melanoma.
- 7 Nov 24
- Journal of immunotherapy (Hagerstown, Md. : 1997)
-
Full paper
Poly (ADP-Ribose) Polymerase 1 Induces Cyclic GMP-AMP Synthase-stimulator of Interferon Genes Pathway Dysregulation to Promote Immune Escape of Colorectal Cancer Cells
- 22 Oct 24
- Journal of Immunotherapy
-
Full paper
Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model.
- 14 Oct 24
- Journal of immunotherapy (Hagerstown, Md. : 1997)
-
Full paper
Immunotherapy in Stage III-IV Colon Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.
- 1 Oct 24
- Journal of immunotherapy (Hagerstown, Md. : 1997)
-
Full paper
Vitexin Inhibits TNBC Progression and Metastasis by Modulating Macrophage Polarization Through EGFR Signaling.
- 1 Oct 24
- Journal of immunotherapy (Hagerstown, Md. : 1997)
-
Full paper
Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics.
- 3 Sep 24
- Journal of immunotherapy (Hagerstown, Md. : 1997)
Scite analysis
Powered by scite_
3.3k articles received 54.8k citations see all
- 1,868 Supporting
- 52,182 Mentioning
- 237 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Journal of Immunotherapy been actively publishing?
Journal of Immunotherapy has been in operation since 1991 till date.
What is the publishing frequency of Journal of Immunotherapy ?
Journal of Immunotherapy published with a Monthly frequency.
How many articles did Journal of Immunotherapy publish last years ?
In 2023, Journal of Immunotherapy published 51 articles.
What is the eISSN & pISSN for Journal of Immunotherapy ?
For Journal of Immunotherapy,eISSN is 1537-4513 and pISSN is1524-9557.
What is Citescore for Journal of Immunotherapy ?
Citescore for Journal of Immunotherapy is 7.9.
What is H index for Journal of Immunotherapy ?
H index for Journal of Immunotherapy is 103.
What is SNIP score for Journal of Immunotherapy ?
SNIP score for Journal of Immunotherapy is 0.8.
What is the SJR for Journal of Immunotherapy ?
SJR for Journal of Immunotherapy is Q1.
Who is the publisher of Journal of Immunotherapy ?
LIPPINCOTT WILLIAMS & WILKINS is the publisher of Journal of Immunotherapy.